AI assistant
El.En. — Investor Presentation 2025
May 20, 2025
4393_cp_2025-05-20_a0965c83-e8cf-4777-b422-bd06bd8242c8.pdf
Investor Presentation
Open in viewerOpens in your device viewer


COMPANY PRESENTATION
Intermonte Northern MidCap Event
Virtual
May 21st , 2025

DISCLAIMER 2

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.



AGENDA 3

1. Overview
- 2. Markets and Growth Drivers
- 3. Our Strategy and Market Approach
- 4. Financial Highlights
- 5. Current Outlook
- 6. Multiples & Comparables

OVERVIEW

OVERVIEW

A PRIMARY PLAYER PROVIDING MEDICAL,INDUSTRIAL AND CONSERVATION LASER SOLUTIONS WORLDWIDE

Hi-Tech industrial group providing laser solutions with proprietary technologies and know how developed over 40 years

Listed on Euronext STAR Milan of Italian Stock Exchange since year 2000 and member of Euronext Tech Leaders
Within Worldwide leaders in its space
Active worldwide on several laser application segments and markets…

…progressively widening its globalwide presence achieving continuous growth over the years

OVERVIEW OUR APPROACH 6

>40 YEARS OF EXPERIENCE

SUBSIDIARIES

10 COUNTRIES WITH DIRECT PRESENCE

14 PLANTS
WE CREATE LIGHT,ENERGY,WAVES

Our energy based systems improve people's well-being and life quality.
In the SURGICAL SECTOR, our minimally invasive technology systems minimize pain, side effects and risks of surgical procedures and hospitalization days.
In the AESTHETIC SECTOR, our systems satisfy the growing desire of individuals to improve their appearance also reducing pathological or painful imperfections.

Our LASER CUTTING and MARKING SYSTEMS Improve the productivity of our customers manufacturing plants also limiting the environmental impact of manufacturing processes minimizing waste, fumes generated by the process, use of chemical additives, and allowing to eliminate the need for inks, solvents or glues within the process.

Our LASER SYSTEMS PRESERVE artworks of the universal heritage ofour communities.

OUR APPROACH



EL.EN. WORLDWIDE 10



UNMATCHED INNOVATION PIPELINE 10

Pigmented lesions





Body contouring and tightening

GROWTH HISTORY (w/o Chinese division) 10


MARKETS AND GROWTH DRIVERS
LASER SURGERY MARKET TRENDS 12

MINIMALLY INVASIVE SURGERIES:
- Lower risks and side effects
- Faster recovery /Shorter hospital stays
- Savings by Private & National Health Systems
- Attractive ROI for surgical services providers
- Rapidly Growing Urology laser market
- Consumables revenue stream in Urology

MEDICAL AESTHETICS MARKET TRENDS 13
- Aging demographics and increasing focus on improving appearance and youthfulness
- Cosmetic procedures as preventive measures for and to slow down the aging process
- Growing interest in non-invasive or minimally invasive procedures and awareness of energybased aesthetic treatments
- Reduction in procedure costs, attracting a broader patient base
- Aesthetic procedures becoming part of lifestyle and increasingly part of people's wellbeing
- Rapid growth expected



MARKET RESEARCHES GROWTH ESTIMATES 14
GLOBAL MEDICAL LASER MARKET
- Mordor Intelligence CAGR 13,4% to 2028
- Fortune business insights CAGR 13,1% to 2030
- Global Market Insights CAGR 14,5% to 2032
- Research and Markets CAGR 13,2% to 2030
- -
With an estimated market size of ≃ \$5 Bln in 2021 including:
- Ophthalmology Dermatology Aesthetics- Dentistry
- Surgical -Gynecology Urology Cardiovascular
AESTHETIC LASER AND ENERGY DEVICES MARKET
• Research and Markets CAGR 9,45% 2023- 2028
\$ 3,7Bn 2023 Market Size
• Tecnavio CAGR 10,9% 2023- 2028 \$ 3,9Bn 2023 Market Size


INDUSTRIAL LASER MARKET TREND 15

Laser cutting applications:
- Laser power increase + Cost reduction: enhanced flexibility, productivity and quality standards in manufacturing processes.
- Automation for increased productivity
- New application verticals
- Building and construction



Laser marking:
- Products identification and traceability
- Minimal environmental impact
Laser processing market:
- Size: \$17,48 billion in 2021
- Expected CAGR to 2030: 9,1%
Source: Grand view research

OUR STRATEGY AND MARKET APPROACH

OUR KNOWLEDGE 17

Aesthetics Surgery Dermatology Physiotherapy Cutting Marking Art Conservation Electronics Optics Photonics Mechanics Fluid dynamics Power electronics Software LASER Technical Knowledge Application Expertise

THE LASER ADVANTAGE 18




- Flexibility
- Speed
- Power
- Precision
- Selectivity
- Effectiveness


MID-TERM STRATEGIC VISION BASED ON: 19
- Continuous investment in R&D: maintaining the unmatched wideness of our product range by innovating existing technologies and developing new ones
- Cooperation with primary research institutions and KOL'S
- Excellent coverage of the target markets based on the widespread and loyal distribution network created over the years
- Focus on innovative products release, technical support and continuous training to our customers
- Unique Multi brand approach


WIDE RANGE OF PRODUCTS IN MEDICAL SECTOR 20



Hair removal Tattoo removal & Pigmented lesions

Body Contouring Skin Rejuvenation


Physiotherapy

Urology




..AND IN INDUSTRIAL SECTOR 21






FINANCIAL HIGHLIGHTS

| INCOME STATEMENT – FY 2024 24 |
|||||
|---|---|---|---|---|---|
| '000 Euro |
31/12/2023 | % | 31/12/2024 | % | % Var |
| Medical | 392 434 |
1% 68 , |
410 401 |
5% 72 , |
6% 4 , |
| Industrial | 183 577 |
31 9% , |
155 444 |
27 5% , |
15 3% - , |
| Revenues | 576 011 |
0% 100 , |
565 846 |
0% 100 , |
8% 1 - , |
| margin Gross |
234 769 |
40 8% , |
245 637 |
43 4% , |
4 6% , |
| Operating Expenses |
50 091 |
7% 8 , |
55 092 |
7% 9 , |
0% 10 , |
| Staff espenses |
92 494 |
16 1% , |
98 770 |
5% 17 , |
6 8% , |
| EBITDA | 92 184 |
16 0% , |
91 775 |
16 2% , |
0 4% - , |
| accruals Depr amort ., ., |
13 965 |
4% 2 , |
13 467 |
4% 2 , |
6% 3 - , |
| EBIT | 78 219 |
13 6% , |
78 309 |
13 8% , |
0 1% , |
| financ income(charges) Net |
(449) | 0 1% - , |
802 | 0 1% , |
|
| Other (expense) income net |
64 | 0% 0 , |
4 993 |
9% 0 , |
1% 7642 , |
| EBT | 835 77 |
13 5% , |
84 104 |
14 9% , |
8 1% , |
| Income taxes |
(22 600) |
9% 3 - , |
(21 227) |
8% 3 - , |
1% 6 - , |
| Discontinued operations |
(5 169) |
9% 0 - , |
(10 372) |
8% 1 - , |
7% 100 , |
| Minorities | (1 827) |
0 3% - , |
(892) | 0 2% - , |
51 2% - , |
| NET INCOME |
48 239 |
4% 8 , |
51 613 |
1% 9 , |
0% 7 , |
The financial statements for this presentation were prepared in accordance with IAS/IFRS accounting principles, reclassifying the contribution of the Chinese industrial cutting division in the assets, liabilities and income statement results from discontinued operations, due to the ongoing negotiations for the sale of the division, in accordance with IFRS5. For a better comparison, the previous year financial statements have also been accordingly reclassified.

BALANCE SHEET – 2024 25

| '000 Euro |
31/12/23 | 31/12/24 | % Var |
|---|---|---|---|
| Total current assets non |
116 304 |
103 237 |
2% 11 - , |
| Working Capital Net |
211 901 |
199 826 |
7% 5 - , |
| receivables/payables Other ST |
(34 876) |
(32 675) |
3% 6 - , |
| financial position Net |
59 877 |
110 559 |
84 6% , |
| liabilities Long term |
16 379 |
16 071 |
1 9% - , |
| Equity Net |
375 458 |
410 802 |
4% 9 , |
| Discontinued operation |
38 630 |
45 926 |
18 9% , |
| capital employed Net |
315 581 |
300 243 |
9% 4 - , |
| Working Capital sales Net on |
8% 36 , |
3% 35 , |
|
| ROCE | 24 8% , |
26 1% , |
|
| (EBIT/Net employed) capital |
|||
| Operating Capex |
11 623 |
13 306 |
The financial statements for this presentation were prepared in accordance with IAS/IFRS accounting principles, reclassifying the contribution of the Chinese industrial cutting division in the assets, liabilities and income statement results from discontinued operations, due to the ongoing negotiations for the sale of the division, in accordance with IFRS5. For a better comparison, the previous year financial statements have also been accordingly reclassified.

2024 FINANCIALS Vs. PROFORMA W/O IFRS5 26
| Financials '000 2024 Euro - |
|||||
|---|---|---|---|---|---|
| P&L | 31/12/2023 | % | 31/12/2024 | % | % Var |
| Revenues | 576 011 |
565 846 |
8% 1 - , |
||
| EBIT | 78 219 |
6% 13 , |
78 309 |
8% 13 , |
1% 0 , |
| 31/12/2023 | % | 31/12/2024 | |||
| unaudited | unaudited | ||||
| NFP | 59 877 |
110 559 |
Financials w/o IFRS5 accounting standard
| P&L | 31/12/2023 | % | 31/12/2024 | % | Var % |
|---|---|---|---|---|---|
| unaudited | unaudited | ||||
| Revenues | 692 290 |
645 881 |
7% 6 - , |
||
| EBIT | 72 736 |
10 5% , |
70 958 |
11 0% , |
2 4% - , |
| 31/12/2023 | % | 31/12/2024 | |||
| unaudited | unaudited | ||||
| NFP | 54 586 |
120 364 |
|||

INCOME STATEMENT – Q1 2025 27
| '000 Euro |
31/03/2024 | % | 31/03/2025 | % | % Var |
|---|---|---|---|---|---|
| unaudited | unaudited | ||||
| Medical | 91 704 |
70 8% , |
99 204 |
70 4% , |
8 2% , |
| Industrial | 37 850 |
29 2% , |
41 696 |
29 6% , |
10 2% , |
| Revenues | 129 555 |
100 0% , |
140 900 |
100 0% , |
8 8% , |
| margin Gross |
680 57 |
44 5% , |
62 947 |
44 7% , |
9 1% , |
| Operating Expenses |
368 14 |
1% 11 , |
132 15 |
10 7% , |
3% 5 , |
| Staff espenses |
23 395 |
1% 18 , |
26 088 |
5% 18 , |
5% 11 , |
| EBITDA | 19 917 |
4% 15 , |
21 726 |
4% 15 , |
1% 9 , |
| accruals Depr amort ., ., |
4 372 |
3 4% , |
4 316 |
3 1% , |
1 3% - , |
| EBIT | 15 544 |
12 0% , |
17 410 |
12 4% , |
12 0% , |
| income(charges) financ Net |
423 | 0 3% , |
(1 111) |
0 8% - , |
|
| (expense) Other income net |
(14) | 0 0% , |
19 | 0 0% , |
|
| EBT | 15 954 |
3% 12 , |
16 318 |
6% 11 , |
3% 2 , |
| 31/12/24 | 31/03/25 | ||||
| unaudited | |||||
| financial position Net |
110 559 |
107 558 |

Cash Flow – Q1 2025 28


**D&A= Depreciation, Accruals and Devaluation
***NWC= Net Working Capital
Revenue Breakdown by Business – Q1 2025 29

Revenue Breakdown by Area – Q1 2025 30




CURRENT OUTLOOK


2025 Guidance 32

Revenues 2025 > Revenues 2024
EBIT 2025 > EBIT 2024


MULTIPLES & COMPARABLES

MULTIPLES 34

| Stockholder's Equity share per |
3 5 , |
|---|---|
| / Price Book Value Adj |
1 8 , |
| /EBIT (95% EBIT) EV |
10 1 , |
| / Sales (95% Sales) EV |
1 2 , |
| El Market En Cap |
@ 780 5 € 9 74 , , |
|---|---|
| financial position Net |
31/03/2025 107 6 @ , |
| m/l Financial investments term |
31/03/2025 @ 7 6 , |
| Value Enterprise |
665 3 , |

MULTIPLES 35

March 31st, 2025
| Price on |
Revenue | % Var |
EBIT | EBIT | MK Cap |
EV | EV/Sales | EV/EBIT | P/Book | |
|---|---|---|---|---|---|---|---|---|---|---|
| Medical/Aesthetic | M ay 19 2025 , |
Rev | % | (*) | (*) | Value | ||||
| InMode | \$14 59 , |
\$78 | -3% | \$16 | 20% | \$990 | \$479 | 1 5 , |
7 7 , |
6 1 , |
| Health Beauty |
\$1 48 , |
\$70 | -15% | \$(12) | -17% | \$186 | \$381 | 1 4 , |
n.a. | 0 4 , |
| Venus | \$2 55 , |
\$14 | -22% | \$(10) | -70% | \$ 3 |
\$24 | 0 4 , |
n.a. | 1 2 , |
| (2) Sisram Medical |
\$0 52 , |
\$349 | -3% | \$35 | 10% | \$245 | \$220 | 0 6 , |
6 3 , |
0 5 , |
| Classys | € 41 54 , |
€ 50 |
45% | € 25 |
50% | € 2 718 |
€ 2 667 |
13 2 , |
26 3 , |
9 3 , |
| Industrial | ||||||||||
| Photonics IPG Co |
\$65 40 , |
\$228 | -10% | \$ 2 |
1 % |
\$2 780 |
\$1 913 |
2 1 , |
261 8 , |
1 3 , |
| Han's Laser |
¥24 55 , |
¥2 912 |
11% | -¥45 | -2% | ¥25 960 |
¥26 561 |
2 3 , |
n.a. | 1 6 , |
| (2) Bystronic |
CHF 281 |
CHF 648 |
-30% | -CHF 84 |
-13% | CHF 513 |
CHF 91 |
0 1 , |
n.a. | 0 8 , |
| Amada | 1 525 JPY |
121 839 JPY |
3 % |
19 292 JPY |
16% | 500 460 JPY |
416 042 JPY |
0 9 , |
5 4 , |
1 0 , |
| Yamazaki | 293 JPY |
804 JPY |
8 % |
1 JPY |
0 % |
1 340 JPY |
2 467 JPY |
0 8 , |
560 6 , |
0 9 , |
| Tech HuaGong |
¥43 20 , |
¥3 342 |
55% | ¥287 | 9 % |
¥42 850 |
¥44 303 |
3 3 , |
38 6 , |
4 0 , |
| El (1) En |
€ 9 74 , |
€ 141 |
9 % |
€ 17 |
12% | € 780 |
€ 665 |
1 2 , |
10 1 , |
1 8 , |
(1) EV and multiplies as for previous slide
(2) Financials @ 31.12.2024
(*) Revenue,Ebit and earnings annualized

El.En. vs. FTSE Star Italy 36


PEERS 37


CONTACTS
El.En. S.P.A. Enrico Romagnoli Investor Relations Manager tel. +39 055-8826807 E-mail: [email protected]
POLYTEMS HIR
Financial Communication, IR and Press Office Bianca Fersini Mastelloni - [email protected] Silvia Marongiu - [email protected] Tel. +39 06-69923324